Search results
Why Moderna Stock Is a No-Brainer Buy Right Now
Motley Fool via Yahoo Finance· 3 days agoCMV is the top infectious cause of birth defects in the U.S. and currently has no approved vaccines. With Merck, Moderna is testing a combination of...
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
Forbes· 6 days agoThe stock price of Moderna has seen a sharp 27% rise in a month, while its peer – BioNTech – has...
Moderna's Combo Flu/Covid Shot Topped Rivals From Sanofi, GSK
Investor's Business Daily· 3 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
2 Dividend Stocks Billionaires Are Buying: Should You? | The Motley Fool
The Motley Fool· 6 days agoMany billionaires are active on Wall Street and largely built their wealth that way. Of course,...
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Investor's Business Daily· 3 days agoThough, notably, Moderna stock fell almost 6% on May 31, the day it won that approval. The company...
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why | The Motley Fool
The Motley Fool· 3 days agoIn that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics (IOVA 7.01%) offered some news that should please its shareholders and ...
Biotech Insiders Share Five Lessons From Pioneering New Medicines
Forbes· 3 days agoWhy does this matter for patients? Enter the cutting-edge biotech and pharma companies who embark on the grueling, risky, and time-consuming path to developing a first-in-class drug. In trials ...
Merck & Co., Inc. (NYSE:MRK) Sees Strong Trading Volume
ETF DAILY NEWS· 8 hours agoShares of Merck & Co., Inc. (NYSE:MRK – Get Free Report) saw strong trading volume on Tuesday . 3,588,327 shares were traded during trading, a decline of 55% from the previous session’s volume ...
Baird Financial Group Inc. Sells 199,862 Shares of Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 10 hours agoBaird Financial Group Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.4% during the 4th quarter, according to its most recent Form 13F filing with the ...
Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs
FierceBiotech· 6 days agoModerna’s methylmalonic acidemia candidate, mRNA-3705, will be developed under the FDA’s START pilot...
